Trigeminal neuralgia is considered to be a debilitating clinical condition and medication is the most important treatment. The application of drugs such as carbazepine, oxcarbazepine or baclofen can provide pain relief in some patients, but there are many people who do not do well with pharmacological treatment. There is some weak evidence that nerve-related treatments may be effective, such as percutaneous interventional hemimelia treatment, stereotactic treatment, and microvascular decompression. Although these treatments provide varying degrees of pain relief, they are associated with many side effects, so modified coronal injections for maxillary and mandibular branch blocks are often used clinically to reduce the risk. The use of steroid hormones in the block can provide more lasting pain relief, but repeated injections of steroids also carry risks. Clinical practice has been looking for drugs that can be used in combination with steroids to reduce the need for multiple hormone injections. Calcitonin may produce analgesic effects, probably due to its ability to regulate prostaglandin and thromboxane synthesis, affect the release of beta-intracerebrosides, and act directly on central nervous system receptors. Nabil Ali Elshiek et al. from Tanta University, Egypt, conducted a randomized controlled clinical trial to evaluate whether local anesthetics and methylprednisolone combined with calcitonin could achieve more durable pain relief in the treatment of trigeminal neuralgia. A total of 63 patients with chronic trigeminal neuralgia (pain lasting more than 6 months) who presented to the pain clinic from January 2012 to December 2013 were included in the trial. 14 were excluded due to atypical facial pain. The remaining 49 patients received 600 mg of oral carbamazepine daily and were evaluated after 2 weeks, and those whose symptoms did not improve continued to receive 150-300 mg of pregabalin daily and were evaluated again after 2 weeks. A total of 16 patients were excluded from the group who were assessed to be effective on medication (>50% reduction in pain scores and >50% reduction in the number of episodes). The remaining 33 patients were randomized into two groups for coronal injection block of the maxillary and mandibular branches of the trigeminal nerve: group 1 applied 0.5% lidocaine 3 ml + methylprednisolone 40 mg + physiological saline 1 ml and group 2 used 0.5% lidocaine 3 ml + methylprednisolone 40 mg + calcitonin 50 units. The two groups were followed up with VAS scores before block, 2 weeks after block, 1 month after block, and every month for 1 year. When the VAS was less than 3, pregabalin was reduced by 75 mg and carbamazepine by 100 mg per week, and if the score was greater than 3, the drug was returned to the last recorded dose. When the oral conventional drug VAS is still greater than 3, the above mentioned blockade can be administered again and the efficacy can be assessed again later. There were no significant differences between the two groups in terms of age, gender, site of involvement, precipitating factors, nerve involvement, or duration of medication prior to surgery. The time to pain relief (VAS < 3) was significantly longer in the calcitonin group (34.7 ± 14.2 weeks) than in the generic group (16.2 ± 12.7 weeks), and the time to pain relief with the second block was 28.5 ± 8.9 weeks. Four of the patients in the generic group no longer required re-blocking compared with 15 in the calcitonin group; six of the generic group had a second block and six required a third block; two of the calcitonin group required a second block and none required a third block. At follow-up, the need for carbamazepine and pregabalin was lower in the calcitonin group than in the generic group, and 7 patients eventually discontinued their medications, compared with 3 in the generic group. VAS scores were lower in the calcitonin group than in the generic group during follow-up. There were no serious side effects during the trial. Seven patients developed injection site hematoma, and six patients in the generic group and four patients in the calcitonin group developed numbness and abnormal sensation in the face, which resolved within 2 weeks. The investigators concluded that the experimental results showed that the addition of calcitonin to local anesthetics and steroid hormones for modified coronal injection block was effective in the treatment of trigeminal neuralgia, and that the method is worthy of preferred consideration in the treatment of trigeminal nerve because it is simple, safe, and radiation-free.